Pocket Program - CROI

Wednesday
March 6 Oral Sessions
Session 45 CROI 2013
248 Phenotypic Differences Between Transmitted/Founder
and Chronic Env Proteins Revealed by Quantitative,
High-Throughput Receptor Affinity Profiling
Kelechi Chikere* 1 , N Webb 1 , T Chou 1 , P Gorry 2 , and B Lee 1
1 Univ of California, Los Angeles, US and 2 Burnet Inst, Melbourne, Australia
249 Transmitted/Founder Infectious Molecular Clones
of Divergent SIV smm Strains Are Infectious and
Replication Competent in vivo
D Ma 1 , H Li 2 , C Xu 1 , B Keele 3 , J Estes 3 , J Lifson 3 , I Pandrea 1 , G Shaw 2 ,
B Hahn 2 , and Cristian Apetrei* 1
1 Ctr for Vaccine Res, Univ of Pittsburgh, PA, US;; 2 Univ of Pennsylvania
Perelman Sch of Med, Philadelphia, US;; and 3 Frederick Natl Lab, MD, US
250 The Number and Genetic Relatedness of
Transmitted/Founder Virus Impact Clinical
Outcome in Vaginal R5 SHIV SF162P3N Transmission
Lily Tsai* 1 , I Tasovski 2 , AR Leda 1 , M Chin 2 , and C Cheng-Mayer 1
1 Aaron Diamond AIDS Res Ctr, New York, NY, US and 2 Temple Univ Sch of
Med, Philadelphia, PA, US
b Wednesday, 1:30-2:30 pm; B308
Session 46–Themed Discussion
(see Session 127 on Tuesday for corresponding Poster Abstracts)
Emergence and Persistence of HPV-associated
Malignancies in the ART Era
Discussants:
Elizabeth Chiao , Baylor Coll of Med, Houston, TX, US
Cynthia Firnhaber, Univ of the Witwatersrand, Johannesburg, South Africa
730 AIDS-defining Cancers in Switzerland 1985-2011:
Separating the Effects of Age and Period
F Schoni-Affolter1 , L Elzi2 , R Weber3 , A Calmy4 , A Bregenzer5 ,
M Cavassini6 , H Furrer7 , G Clifford8 , M Egger1 , Olivia Keiser* 1 ,
and Swiss HIV Cohort Study
1 2 3 Univ of Bern, Switzerland;; Univ Hosp Basel, Switzerland;; Univ Hosp
Zurich, Switzerland;; 4Geneva Univ Hosp, Switzerland;; 5Cantonal Hosp St
Gallen, Switzerland;; 6Univ Hosp Lausanne, Switzerland;; 7Univ Hosp Bern,
Switzerland;; and 8Intl Agency for Res on Cancer
731 Incidence of AIDS-defining and Non-AIDS-defining
Cancers following Expansion of ART: Botswana
2003-2008
Scott Dryden-Peterson* 1,2,3 , H Medhin4 , G Seage2 , M Pusoentsi4 , S El-Halabi4 ,
T Rebbeck5 , G Suneja5 , M Mmalane3 , M Essex2,3 , and S Lockman1,2,3 1 2 Brigham and Womens Hosp, Boston, MA, US;; Harvard Sch of Publ Hlth,
Boston, MA, US;; 3Botswana Harvard AIDS Inst Partnership, Gaborone;;
4 5 Botswana Ministry of Hlth, Gaborone;; and Univ of Pennsylvania,
Philadelphia, US
732 Frequent Detection of Human Papillomavirus before
and after Initiation of ART among HIV + Women:
Uganda
Anne Rositch* 1 , P Gravitt1,2 , A Tobian1,3 , K Newell4 , T Quinn3,5 ,
D Serwadda6 , P Ssebbowa6 , V Kiggundu6 , R Gray1,6 , and S Reynolds3,5 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;;
2 3 Perdana Univ Grad Sch of Med, Serdang, Malaysia;; Johns Hopkins Univ
Sch of Med, Baltimore, MD, US;; 4Frederick Natl Lab for Cancer Res, MD, US;;
5 6 NIAID, NIH, Bethesda, MD, US;; and Rakai Hlth Sci Prgm, Entebbe, Uganda
733 HPV Genotype Impacts T Cell Activation and
Cervical Cellular Infiltrates Irrespective of Lesion
Grade in ART-suppressed Human Papillomavirus/
HIV-1 Co-infected Women
Emmanouil Papasavvas* 1 , D Glencross2,3 , N Mayisela4 , T Omar2 ,
A-L Williamson5,6 , M Siminya4 , X Yin1 , Q Liu1 , C Firnhaber2,4 ,
and L Montaner1 1 2 The Wistar Inst, Philadelphia, PA, US;; Univ of the Witwatersrand,
Johannesburg, South Africa;; 3Natl Hlth Lab Svc, Johannesburg, South
Africa;; 4Right to Care, Johannesburg, South Africa;; 5Univ of Cape Town,
South Africa;; and 6Natl Hlth Lab Svc, Cape Town, South Africa
734 Human Papillomavirus, Cervical Neoplasia, and
Invasive Cancer in Women with HIV-2 Infection in
the ART Era: Senegal, West Africa
S Hawes1 , Q Feng1 , S Ba2 , M Toure1,2 , M-P Sy2 , F Traore2 , R Smith1 , N Kiviat1 ,
PS Sow1,2 , Geoffrey Gottlieb* 1 , and UW-Dakar HIV-2 Study Group
1 2 Univ of Washington, Seattle, US and Ctr Hosp Univ de Fann, Univ Cheikh
Anta Diop de Dakar, Senegal
735 Anal Human Papillomavirus Infection in HIV +
Patients: Prevalence, Incidence, and Predictors
of High-risk Human Papillomavirus Infection
Alberto Borghetti* 1 , P Cattani2 , G Maria3 , M Sanguinetti2 ,
S D’Onghia2 , R Santangelo2 , S Marchetti2 , R Cauda1 , A De Luca1,4 ,
and S Di Giambenedetto1 1Inst of Clin Infectious Diseases, Catholic Univ of Sacred Heart, Rome,
Italy;; 2Inst of Microbiology, Catholic Univ of Sacred Heart, Rome, Italy;;
3Inst of Clin and Surgical Therapy, Catholic Univ of Sacred Heart, Rome,
Italy;; and 4Siena Univ Hosp, Italy
20 20th Conference on Retroviruses and Opportunistic Infections
736 The Effect of Protease Inhibitors on the Incidence of
HIV-associated Squamous Cell Carcinoma of the Anus
Pamela Mbang* 1 , M Kowalkowski 2 , and E Chiao 1,2
1 Baylor Coll of Med, Houston, TX, US and 2 Houston Hlth Svcs Res and Devt
Ctr of Excellence, Michael E DeBakey VAMC, TX, US
737 Prevalence and Genotypes of Human Papillomavirus at
Penile and Perianal Sites among HIV + and HIV – MSM
Han-Zhu Qian* 1 , Y Hu 2 , L Yin 1 , Y Ruan 2 , Y Shao 2 , and S Vermund 1
1 Vanderbilt Univ, Nashville, TN, US and 2 Natl Ctr for STD/AIDS Control
and Prevention of China CDC, Beijing
b Wednesday, 1:30-2:30 pm; B313
Session 47–Themed Discussion
(see Session 149 on Tuesday for corresponding Poster Abstracts)
Mechanisms of Immune Reconstitution
Discussants:
Brigitte Autran, Univ Pierre and Marie Curie, Pitie-Salpetriere Hosp,
Paris, France (invited)
Robert Colebunders, Inst of Tropical Med Antwerp, Belgium
859 Early ART after Cryptococcal Meningitis Increases
Cerebrospinal Fluid Macrophage Activation and
Aberrant Th2 Responses in a Multisite Randomized Trial
James Scriven* 1,2 , J Rhein 3,4 , K Huppler Hullsiek 4 , M von Hohenberg 4 ,
G Linder 4 , M Rolfes 4 , D Williams 3,4 , D Meya 3,4,5 , G Meintjes 2 , D Boulware 4 ,
and Cryptococcal Optimal ART Timing Trial
1 Liverpool Sch of Tropical Med, UK;; 2 Univ of Cape Town, South
Africa;; 3 Infectious Disease Inst, Kampala, Uganda;; 4 Univ of Minnesota,
Minneapolis, US;; and 5 Makerere Univ, Kampala, Uganda
860 Impact of TB-associated Immune Reconstitution
Inflammatory Syndrome on T Cell Activation and
Reconstitution in Highly Immunosuppressed HIV/TB
Co-infected Patients Starting ART
V Haridas 1 , P Pean 2 , L Jasenosky 1 , Y Madec 3 , D Laureillard 4 , L Borand 2 ,
O Marcy 5 , T Sok 5 , X Blanc 6 , and Anne Goldfeld* 1,5
1 Prgm in Cellular and Molecular Med, Childrens Hosp, Boston, MA, US;;
2 Inst Pasteur du Cambodge, Phnom Penh, Cambodia;; 3 Inst Pasteur, Paris,
France;; 4 ANRS, Ho Chi Minh City, Vietnam;; 5 Cambodian Hlth Committee,
Phnom Penh;; and 6 Bicetre Hosp Assistance Publ-Hosp de Paris, France
861 Ex vivo Interferon Gamma Release Assay Responses
to Cryptococcal Capsule Antigen Predict Outcomes
of Death or Immune Reconstitution Inflammatory
Syndrome after Cryptococcal Meningitis
Darin Wiesner* 1 , A Akamps 2 , J Rhein 1,3 , D Williams 1,3 , D Meya 1,2,3 ,
P Bohjanen 1 , K Nielsen 1 , D Boulware 1 , and Cryptococcal Optimal ART
Timing Trial
1 Univ of Minnesota, Minneapolis, US;; 2 Makerere Univ, Kampala, Uganda;;
and 3 Infectious Disease Inst, Kampala, Uganda
862 Biomarkers of CD4 + T Cell Activation in HIV +
Patients Developing Mycobacterium tuberculosisassociated
Immune Reconstitution Inflammatory
Syndrome
Lisa Chakrabarti* 1 , C Boucherie 2 , F Bugault 1 , M-C Cumont 1 ,
C Roussillon 2 , G Breton 3 , O Patey 4 , L Richert 2 , G Chene 2,5 , O Lortholary 6 ,
and ANRS 129 BKVIR-CYTOK Substudy Group
1 Inst Pasteur, Paris, France;; 2 INSERM U897, Univ Bordeaux, France;;
3 Hosp de La Pitie-Salpetriere, Paris, France;; 4 Hosp Villeneuve St-Georges,
France;; 5 CHU de Bordeaux, France;; and 6 Univ Paris Descartes, Hosp
Necker Enfants Malades, APHP, Paris, France
b Wednesday, 1:30-2:30 pm; Ballroom 3-4
Session 48–Themed Discussion
(see Session 198 on Tuesday for corresponding Poster Abstracts)
Adherence and Retention in RLS
Discussants:
David Bangsberg, Massachusetts Gen Ctr for Global Hlth, Boston, US
Wafaa El-Sadr, Columbia Univ, Harlem Hosp Ctr, New York, NY, US
1101 Validating Measures of Distance to HIV Clinic in
Rural Uganda and Its Impact on Clinic Attendance
Mark Siedner* 1 , A Lankowski 1 , A Tsai 1,2 , C Muzoora 3 , P Hunt 4 ,
J Martin 4 , J Haberer 1 , and D Bangsberg 1,5
1 Massachusetts Gen Hosp Ctr for Global Hlth, Boston, US;; 2 Massachusetts
Gen Hosp, Boston, US;; 3 Mbarara Univ of Sci and Tech, Uganda;; 4 Univ
of California, San Francisco, US;; and 5 Ragon Inst of MGH, MIT, and
Harvard Med Sch, Boston, US
1102 Site and Program Determinants of Patient Retention
in HIV Care: Nigeria
Chinenye Ugoji* 1 , R Ake-Uzoigwe 1 , MY Ladele 1 , C Akolo 1 , G Mendy 1 ,
P Dakum 1 , M Charurat 2 , D Onotu 3 , O Nwanyanwu 3 , and W Blattner 2
1 Inst of Human Virology Nigeria, Abuja;; 2 Inst of Human Virology, Univ of
Maryland, Baltimore, US;; and 3 Ctr for Disease Control, Nigeria